This possibility is supported by very recent observations in non-viral HCC such that increased hepatic CD8+ T cells resulted in increased incidence of liver damage, NASH, and HCC in preclinical models as well as in patients with NASH (Pfister et al., 2021). This evidence concerns the gene CD8A and metabolic dysfunction-associated steatohepatitis.